{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:58:20Z","timestamp":1785398300030,"version":"3.56.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>IgA vasculitis (IgAV) and IgA nephropathy (IgAN) have historically been treated as distinct disease entities in clinical practice and in drug development, despite growing evidence speaking to a shared pathogenesis. Recent years have seen an explosion in therapeutic trials in the IgAN space, with multiple approvals of targeted therapies and a shifting paradigm of care; meanwhile, IgAV has lagged behind with a paucity of randomized trials. What can rheumatologists learn from IgAN, and can IgAV patients benefit from therapeutic advances in IgAN?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>In this article, we will compare and contrast the epidemiology and clinical presentations of IgAV and IgAN, and explore the evidence supporting a shared pathogenesis including the \u2018four hit hypothesis\u2019. We will review emerging therapies in IgAN and their biologic basis for the rheumatology audience, and discuss how lessons learned in IgAN might be applied to IgAV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Rheumatologists should be aware of the therapeutic advances in IgAN, which may inform future management of IgAV patients, particularly those with renal involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001171","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:00:06Z","timestamp":1781247606000},"page":"336-342","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists"],"prefix":"10.1097","volume":"38","author":[{"given":"Julia A.","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Gewurz-Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00281-021-00874-9","article-title":"IgA vasculitis","volume":"43","author":"Pillebout","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"(2 Suppl 41)","key":"R2-20260730","first-page":"S26","article-title":"Henoch-Schonlein's purpura in adults versus children\/adolescents: a comparative study","volume":"24","author":"Uppal","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/art.40178","article-title":"Characteristics and management of IgA vasculitis (Henoch-Schonlein) in adults: data from 260 patients included in a French multicenter retrospective survey","volume":"69","author":"Audemard-Verger","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3899\/jrheum.220503","article-title":"Immunoglobulin A vasculitis following COVID-19: a French Multicenter Case Series","volume":"49","author":"Ramdani","year":"2022","journal-title":"J Rheumatol"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-021-01013-x","article-title":"IgA vasculitis in adults: a rare yet challenging disease","volume":"23","author":"Yaseen","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch-Schonlein Purpura): an update on treatment","volume":"13","author":"Castaneda","year":"2024","journal-title":"J Clin Med"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"102490","DOI":"10.1016\/j.autrev.2020.102490","article-title":"Rituximab treatment for IgA vasculitis: a systematic review","volume":"19","author":"Hernandez-Rodriguez","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1631\/jzus.B1400335","article-title":"Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schonlein purpura nephritis: a retrospective study","volume":"16","author":"Han","year":"2015","journal-title":"J Zhejiang Univ Sci B"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0002-9343(88)90019-8","article-title":"IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States?","volume":"84","author":"Julian","year":"1988","journal-title":"Am J Med"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1523-1755.2001.059003823.x","article-title":"What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis?","volume":"59","author":"Davin","year":"2001","journal-title":"Kidney Int"},{"key":"R12-20260730","article-title":"Genome-wide studies define new genetic mechanisms of IgA vasculitis","author":"Liu","year":"2024","journal-title":"medRxiv"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"(4S)","key":"R14-20260730","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"R15-20260730","first-page":"939","article-title":"IgA glomerular deposits in renal disease","volume":"1","author":"Berger","year":"1969","journal-title":"Transplant Proc"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2215\/CJN.0000000000000398","article-title":"Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis","volume":"19","author":"Barbour","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ndt\/gfae143","article-title":"Clinical and histological comparison of IgA nephritis and renal IgA vasculitis","volume":"40","author":"Friedrich","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000519973","article-title":"New insights into the pathogenesis and treatment strategies in IgA nephropathy","volume":"2","author":"Scionti","year":"2022","journal-title":"Glomerular Dis"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41581-024-00850-0","article-title":"The role of antibody glycosylation in autoimmune and alloimmune kidney diseases","volume":"20","author":"Beyze","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"R21-20260730","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00467-007-0623-y","article-title":"Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schonlein purpura","volume":"22","author":"Lau","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R22-20260730","doi-asserted-by":"crossref","first-page":"e0188718","DOI":"10.1371\/journal.pone.0188718","article-title":"Biomarkers of IgA vasculitis nephritis in children","volume":"12","author":"Pillebout","year":"2017","journal-title":"PLoS One"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"e11691","DOI":"10.1371\/journal.pone.0011691","article-title":"B cell activating factor (BAFF) and T cells cooperate to breach B cell tolerance in lupus-prone New Zealand Black (NZB) mice","volume":"5","author":"Chang","year":"2010","journal-title":"PLoS One"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ekir.2019.08.015","article-title":"Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis","volume":"4","author":"Suzuki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/bmj.3.5875.326","article-title":"Glomerular deposition of properdin in Henoch-Schonlein syndrome and idiopathic focal nephritis","volume":"3","author":"Evans","year":"1973","journal-title":"Br Med J"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00467-022-05585-3","article-title":"Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schonlein purpura nephropathy","volume":"38","author":"Wu","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"R27-20260730","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1093\/ckj\/sfad236","article-title":"Urinary markers of the alternative and lectin complement pathway are increased in IgA vasculitis nephritis","volume":"16","author":"Marro","year":"2023","journal-title":"Clin Kidney J"},{"key":"R28-20260730","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.ajkd.2004.10.020","article-title":"Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis","volume":"45","author":"Hisano","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R29-20260730","doi-asserted-by":"crossref","first-page":"151571","DOI":"10.1016\/j.semnephrol.2025.151571","article-title":"IgA vasculitis and IgA nephropathy: two sides of the same coin?","volume":"44","author":"Pillebout","year":"2024","journal-title":"Semin Nephrol"},{"key":"R30-20260730","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"R31-20260730","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ndt\/gfaf189","article-title":"Albuminuria and kidney disease progression in IgA nephropathy in China","volume":"41","author":"Yu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"R32-20260730","doi-asserted-by":"crossref","first-page":"170.e1","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"R33-20260730","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients With IgA nephropathy: the TESTING Randomized Clinical Trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"R34-20260730","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"R35-20260730","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"R36-20260730","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"R37-20260730","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"R38-20260730","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"R39-20260730","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"R40-20260730","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"R41-20260730","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"R42-20260730","first-page":"76","article-title":"Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy","volume":"41","author":"Zhang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"R43-20260730","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12969-025-01159-3","article-title":"Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study","volume":"23","author":"Ma","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"key":"R44-20260730","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","article-title":"Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"R45-20260730","doi-asserted-by":"crossref","first-page":"1564242","DOI":"10.3389\/fimmu.2025.1564242","article-title":"Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"(Suppl 2)","key":"R46-20260730","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Fontan","year":"2023","journal-title":"Clin Kidney J"},{"key":"R47-20260730","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"R48-20260730","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"R49-20260730","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"R50-20260730","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:00:41Z","timestamp":1785394841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001171","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}